State of Wisconsin Investment Board boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 25.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,299,452 shares of the medical equipment provider’s stock after acquiring an additional 473,525 shares during the quarter. State of Wisconsin Investment Board owned 0.17% of Boston Scientific worth $57,003,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Valeo Financial Advisors LLC bought a new stake in Boston Scientific in the third quarter valued at about $138,000. Steward Partners Investment Advisory LLC bought a new stake in Boston Scientific in the third quarter valued at about $139,000. Cerebellum GP LLC bought a new stake in Boston Scientific in the fourth quarter valued at about $126,000. Ironwood Investment Counsel LLC bought a new stake in Boston Scientific in the third quarter valued at about $204,000. Finally, Perkins Capital Management Inc. bought a new stake in Boston Scientific in the third quarter valued at about $204,000. 89.84% of the stock is currently owned by institutional investors and hedge funds.
In other news, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $26.66, for a total transaction of $413,230.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Valley Gold Master Fund L. Sun acquired 408,006 shares of the business’s stock in a transaction that occurred on Tuesday, November 28th. The stock was acquired at an average price of $0.45 per share, for a total transaction of $183,602.70. Insiders have sold 177,032 shares of company stock worth $4,648,733 over the last three months. 0.74% of the stock is owned by insiders.
A number of analysts recently weighed in on the stock. Jefferies Group reissued a “neutral” rating on shares of Boston Scientific in a research note on Friday, February 2nd. Zacks Investment Research raised shares of Boston Scientific from a “sell” rating to a “hold” rating in a research note on Tuesday, January 30th. TheStreet raised shares of Boston Scientific from a “c+” rating to a “b” rating in a research note on Thursday, January 18th. Canaccord Genuity reaffirmed a “buy” rating on shares of Boston Scientific in a research note on Wednesday, January 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a research note on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Boston Scientific currently has a consensus rating of “Buy” and a consensus price target of $31.00.
Shares of Boston Scientific Corporation (BSX) opened at $27.09 on Friday. Boston Scientific Corporation has a 52 week low of $23.29 and a 52 week high of $29.93. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. The company has a market cap of $36,815.39, a P/E ratio of 387.00, a PEG ratio of 1.94 and a beta of 0.81.
Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.34. Boston Scientific had a net margin of 1.15% and a return on equity of 24.04%. The business had revenue of $2.41 billion for the quarter, compared to analysts’ expectations of $2.39 billion. During the same period in the prior year, the firm earned $0.30 earnings per share. Boston Scientific’s revenue was up 9.9% compared to the same quarter last year. analysts anticipate that Boston Scientific Corporation will post 1.37 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “State of Wisconsin Investment Board Has $57 Million Position in Boston Scientific Corporation (BSX)” was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2018/02/16/state-of-wisconsin-investment-board-has-57-million-position-in-boston-scientific-corporation-bsx.html.
Boston Scientific Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.